The 2022 top 100 biopharma investors: A look back on boom times
RA Capital dominated the crossover game in 2021, running the table as a host of biotechs angled for a quick leap onto the public market. The RA crew, headed by Peter Kolchinsky and Raj Shah, even beat out OrbiMed last year on the total number of new deals executed, with both representing big spikes over 2020 deal levels.
OrbiMed, though, was involved with a larger amount of cash going into new deals, typical for the heavyweight player in this industry. And if you explore the charts below the top 100, you’ll see how the rush to the market helped tilt the scales toward earlier stage biotechs.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.